{
  "id": 19376108,
  "title": "FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk",
  "url": "https://urgent.news/2026/11/10/fda-initiates-labeling-changes-for-glp-1s-due-to-rare-but-serious-eye",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T16:46:51.000Z",
  "source": {
    "name": "Healthline News",
    "slug": "healthline-news",
    "url": "https://www.healthline.com/health-news/fda-safety-labeling-changes-glp-1-drugs-eye-diesease-risk"
  },
  "original_language": "en",
  "account": "The FDA has mandated new warnings on the labels of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, Zepbound, and others, due to a potential increased risk of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). This condition can cause sudden, painless vision loss in one eye. While GLP-1 medications are approved for treating type 2 diabetes and weight management, the FDA emphasized that the benefits of these drugs still outweigh their risks when used as directed. Symptoms of NAION include sudden vision loss, blind spots, tunnel vision, distorted colors, and blurry spots in the center of vision. The FDA's decision stems from a 2024 JAMA Ophthalmology study that found a higher risk of NAION among people prescribed semaglutide, the active ingredient in Ozempic and Wegovy, compared to those on other diabetes or weight-loss drugs. Risk factors for NAION include smoking, a history of NAION in one eye, and certain health conditions such as diabetes, high blood pressure, sleep apnea, kidney disease, and anemia. Despite the warning, the FDA maintains that the overall risk of NAION remains very small for patients using GLP-1 medications as directed.",
  "summary": "A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss. Regulators in the…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}